No Data
Guangxi Liuyao Group (603368): The three major business segments are gradually improving, accelerating expansion outside the province.
Event: In the third quarter of 2024, guangxi liuyao group achieved revenue of 5.351 billion yuan, a year-on-year increase of 1.49%; achieved net income attributable to the parent of 0.252 billion yuan, a year-on-year increase of 8.68%; in the first three quarters of 2024, achieved revenue
Guangxi Liuyao Group Co., Ltd. Report for the Third Quarter of 2024
Guangxi Liuyao Group (603368.SH) released its performance for the first three quarters, with a net income of 0.716 billion yuan, a year-on-year increase of 6.13%.
Guangxi Liuyao Group (603368.SH) disclosed the third quarter report of 2024, achieving a revenue of 15...
Guangxi Liuyao Group (603368.SH): The net income for the first three quarters was 0.716 billion yuan, a year-on-year increase of 6.13%.
格隆汇October 29th - Guangxi Liuyao Group (603368.SH) released its third quarter report, with revenue for the first three quarters reaching 15.99 billion yuan, a year-on-year increase of 2.41%, net income of 0.716 billion yuan, a year-on-year increase of 6.13%, non-net profit of 0.7 billion yuan, a year-on-year increase of 5.20%, and basic earnings per share of 1.87 yuan.
Guangxi Liuyao Group (603368.SH): 36.8421 million shares of restricted shares will be lifted on October 24th.
Guangxi Liuyao Group (603368.SH) announced that the total number of stocks listed this time is 36.8421 million shares. The stock listing date is October 24, 2024.
Guangxi Liuyao Group (603368.SH): As of August 31, 2024, the production capacity of traditional Chinese medicine formula granules has reached 1000 tons.
Guangxi Liuyao Group (603368.SH) announced that the company's traditional chinese medicine formulation granule project capacity: the total planned capacity of the project is 3,000 tons, with an initial capacity of 1,500 tons. From January to August 2024, the company actively promoted equipment introduction, process optimization, and equipment technological upgrading to accelerate capacity improvement. As of August 31, 2024, the capacity of the traditional chinese medicine formulation granule project reached 1,000 tons, effectively meeting the company's market expansion needs. At the same time, the company further accelerated capacity follow-up based on market development progress to ensure the company's supply advantages of traditional chinese medicine formulation granules. The company has a variety of traditional chinese medicine formulation granule varieties.
No Data
No Data